美国 · SEC FORM 4
ARROWHEAD PHARMACEUTICALS, INC.
ARWR · Nasdaq · CIK 0000879407 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
8 同一窗口内观察到的 Form 4 交易行
7 sales · 1 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2024-04-18 · Lu Hongbo.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -27.8%
- 3M
- -26.8%
- 6M
- -4.5%
- 12M
- +63.9%
波动率与流动性
- 波动率
- 67.1%
- Beta
- —
- 平均每日成交额
- USD 117.4M
估值
- 市值
- —
- P/E
- —
基本面
- 利润率
- -0.2%
- ROE
- -0.3%
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-07 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：利润率, ROE · 财年截止日：2025-09-30 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 10,760,463
- 上期报告
- 9,272,290
- 日均成交量
- 2,669,000
- 回补天数
- 4.0
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2024-04-18 | Lu Hongbo | 买入 (P) | Common Stock | 500 | USD 22.00 | USD 11,000 | SEC 申报 ↗ |
| 2024-04-10 | Lu Hongbo | 买入 (P) | Common Stock | 500 | USD 25.00 | USD 12,500 | SEC 申报 ↗ |
| 2024-04-02 | Lu Hongbo | 买入 (P) | Common Stock | 150 | USD 27.34 | USD 4,101 | SEC 申报 ↗ |
| 2024-03-26 | Lu Hongbo | 买入 (P) | Common Stock | 850 | USD 27.50 | USD 23,375 | SEC 申报 ↗ |
| 2024-03-22 | Lu Hongbo | 买入 (P) | Common Stock | 400 | USD 28.00 | USD 11,200 | SEC 申报 ↗ |
| 2024-03-20 | Lu Hongbo | 买入 (P) | Common Stock | 1,000 | USD 27.50 | USD 27,500 | SEC 申报 ↗ |
| 2024-03-19 | Lu Hongbo | 买入 (P) | Common Stock | 1,000 | USD 28.00 | USD 28,000 | SEC 申报 ↗ |
| 2024-03-18 | Lu Hongbo | 买入 (P) | Common Stock | 1,000 | USD 27.49 | USD 27,490 | SEC 申报 ↗ |
| 2021-12-28 | GIVEN DOUGLAS B | 买入 (P) | Common Stock | 655 | USD 66.37 | USD 43,472 | SEC 申报 ↗ |
| 2020-10-08 | De Backer Marianne | 买入 (P) | Common Stock | 1,000 | USD 50.47 | USD 50,465 | SEC 申报 ↗ |
| 2020-06-15 | De Backer Marianne | 买入 (P) | Common Stock | 500 | USD 31.33 | USD 15,665 | SEC 申报 ↗ |
| 2020-04-15 | De Backer Marianne | 买入 (P) | Common Stock | 500 | USD 35.40 | USD 17,700 | SEC 申报 ↗ |
| 2020-03-16 | De Backer Marianne | 买入 (P) | Common Stock | 500 | USD 23.94 | USD 11,970 | SEC 申报 ↗ |
| 2020-03-12 | De Backer Marianne | 买入 (P) | Common Stock | 500 | USD 24.80 | USD 12,400 | SEC 申报 ↗ |
| 2020-03-11 | De Backer Marianne | 买入 (P) | Common Stock | 500 | USD 28.60 | USD 14,300 | SEC 申报 ↗ |
Form 4 申报证据
81 transaction lines in the latest 365-day window; 477 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-18 | PERRY MICHAEL S | 卖出 (S) | Common Stock | 11,600 | USD 87.30 | USD 1,012,680 | SEC 申报 ↗ |
| 2026-08-18 | OLUKOTUN ADEOYE Y | 卖出 (S) | Common Stock | 2,000 | USD 86.96 | USD 173,920 | SEC 申报 ↗ |
| 2026-06-15 | Cohen Matthew Gregory | 奖励／授予 (A) | Common Stock | 11,882 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-18 | PERRY MICHAEL S | 卖出 (S) | Common Stock | 11,600 | USD 87.30 | USD 1,012,680 | SEC 申报 ↗ |
| 2026-08-18 | OLUKOTUN ADEOYE Y | 卖出 (S) | Common Stock | 2,000 | USD 86.96 | USD 173,920 | SEC 申报 ↗ |
| 2026-06-15 | Cohen Matthew Gregory | 奖励／授予 (A) | Common Stock | 11,882 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-12 | Lu Hongbo | 卖出 (S) | Common Stock | 2,970 | USD 76.88 | USD 228,334 | SEC 申报 ↗ |
| 2026-04-23 | Hamilton James C | 卖出 (S) | Common Stock | 10,000 | USD 75.00 | USD 750,000 | SEC 申报 ↗ |
| 2026-04-22 | Apel Daniel Joseph | 卖出 (S) | Common Stock | 13,095 | USD 71.35 | USD 934,285 | SEC 申报 ↗ |
| 2026-03-05 | Hamilton James C | 卖出 (S) | Common Stock | 10,000 | USD 64.19 | USD 641,900 | SEC 申报 ↗ |
| 2026-01-06 | O'Brien Patrick | 赠与 (G) | Common Stock | 980 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-06 | O'Brien Patrick | 奖励／授予 (A) | Common Stock | 75,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-06 | Hamilton James C | 奖励／授予 (A) | Common Stock | 75,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-06 | Apel Daniel Joseph | 奖励／授予 (A) | Common Stock | 75,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-05 | O'Brien Patrick | 卖出 (S) | Common Stock | 49,493 | USD 63.11 | USD 3,123,349 | SEC 申报 ↗ |
| 2026-01-05 | Hamilton James C | 卖出 (S) | Common Stock | 40,164 | USD 63.11 | USD 2,534,661 | SEC 申报 ↗ |
| 2026-01-02 | Anzalone Christopher Richard | 卖出 (S) | Common Stock | 13,187 | USD 66.10 | USD 871,703 | SEC 申报 ↗ |
| 2025-12-31 | O'Brien Patrick | 赠与 (G) | Common Stock | 560 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-29 | Anzalone Christopher Richard | 卖出 (S) | Common Stock | 51,726 | USD 69.13 | USD 3,575,575 | SEC 申报 ↗ |
| 2025-12-29 | Anzalone Christopher Richard | 期权行权／转换 (M) | Common Stock | 51,726 | USD 6.15 | USD 318,115 | SEC 申报 ↗ |
| 2025-12-26 | Ferrari Mauro | 卖出 (S) | Common Stock | 7,530 | USD 70.00 | USD 527,100 | SEC 申报 ↗ |
| 2025-12-22 | Anzalone Christopher Richard | 卖出 (S) | Common Stock | 12,586 | USD 68.44 | USD 861,340 | SEC 申报 ↗ |
| 2025-12-19 | Waddill William D. | 卖出 (S) | Common Stock | 8,367 | USD 67.65 | USD 566,038 | SEC 申报 ↗ |
| 2025-12-19 | Vakiener Victoria | 卖出 (S) | Common Stock | 10,040 | USD 67.68 | USD 679,491 | SEC 申报 ↗ |
| 2025-12-19 | OLUKOTUN ADEOYE Y | 卖出 (S) | Common Stock | 10,000 | USD 67.66 | USD 676,623 | SEC 申报 ↗ |
| 2025-12-19 | Anzalone Christopher Richard | 卖出 (S) | Common Stock | 13,445 | USD 67.66 | USD 909,683 | SEC 申报 ↗ |
| 2025-12-17 | Anzalone Christopher Richard | 卖出 (S) | Common Stock | 85,000 | USD 64.04 | USD 5,443,462 | SEC 申报 ↗ |
| 2025-12-16 | Waddill William D. | 奖励／授予 (A) | Common Stock | 7,819 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-16 | Vakiener Victoria | 奖励／授予 (A) | Common Stock | 7,819 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-16 | PERRY MICHAEL S | 奖励／授予 (A) | Common Stock | 7,819 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-16 | OLUKOTUN ADEOYE Y | 奖励／授予 (A) | Common Stock | 7,819 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-16 | Lu Hongbo | 奖励／授予 (A) | Common Stock | 7,819 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-16 | INGRAM DOUGLAS S | 奖励／授予 (A) | Common Stock | 7,819 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | ARWR |
| CIK | 0000879407 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 477 transaction lines from 2020-01-01 to 2026-08-18 19 P purchase lines · 312 S sale lines · 146 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.